PMI Picard Medical, Inc.
Price Chart
Executive Summary
Picard Medical issued a shareholder letter from Chairman Richard Fang recapping 2025 results ($4.9M revenue, +12.5% YoY) and Q1 2026 performance ($1.2M revenue, +85% YoY; 24% gross margin vs. -58% a year ago). The letter also discloses that the company received NYSE American notices regarding stockholders' equity requirements and has until June 7, 2026 to submit a compliance plan. While operational metrics improved, the company remains unprofitable with a going-concern qualification and faces a near-term delisting risk.
Actionable Insight
The shareholder letter is a routine update with no new material financial guidance, but the NYSE American listing notice is a concrete risk. Monitor the June 7 compliance plan deadline — failure to submit or gain acceptance could trigger delisting proceedings. The improved Q1 revenue and gross margin trajectory is positive, but the going-concern qualification and $14M market cap make the equity highly speculative.
Key Facts
- FY2025 total revenue $4.9M, up 12.5% YoY; product revenue $4.7M (96% of total)
- Q1 2026 revenue $1.2M, up 85% YoY; gross profit turned positive at 24% margin vs. -58% in Q1 2025
- IPO raised $17.4M net equity; additional $9.7M debt financing; year-end cash $11.5M vs. $0.1M at YE 2024
- Q1 2026: repaid ~$7.4M senior secured debt in cash, settled $2.1M through equity
- Post-Q1: raised $5.0M gross in public offering; entered warrant exchange eliminating ratchet provisions
- Auditors included a going-concern qualification in 2025 financial statements
- Received NYSE American notices regarding stockholders' equity; compliance plan due June 7, 2026
- Emperor TAH second-gen animal testing completed; seeking regulatory approval as early as 2028
- Pending FDA decision on PMA supplement to expand indications to bridge-to-candidacy patients
Financial Impact
Q1 2026 revenue $1.2M (85% YoY growth); gross margin improved to 24% from -58%; $5.0M post-quarter equity raise; $7.4M debt principal repaid in cash during Q1
Risk Factors
- NYSE American delisting risk if compliance plan not accepted by June 7, 2026
- Going-concern qualification in audited financials; company not yet profitable
- Regulatory uncertainty for Emperor TAH approval (target 2028) and pending PMA supplement
- Small market cap ($14M) and low liquidity amplify volatility
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-005779 |
| Document: picardmedical_ex99-1.htm | 0001829126-26-005779 |
| Document: 0001829126-26-005779-index-headers.html | 0001829126-26-005779 |
| Document: 0001829126-26-005779-index.html | 0001829126-26-005779 |
| Document: 0001829126-26-005779.txt | 0001829126-26-005779 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
Press Release
| $0.2700 $0.3080 | ▲ +14.07% | ▲ +14.77% | $0.2582 (−4.37%) |
|
Jun 2, 2026
3d ago
|
8-K
| $0.2700 $0.3080 | ▼ −14.07% | ▼ −14.77% | $0.2582 (+4.37%) |
|
Jun 1, 2026
4d ago
|
EFFECT
| — | awaiting T+1 | — | — |
|
May 29, 2026
7d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 29, 2026
7d ago
|
Press Release
| $0.1480 $0.1684 | ▲ +13.78% | ▲ +13.51% | $0.2582 (+74.46%) |
|
May 21, 2026
15d ago
|
Press Release
| $0.1410 $0.1510 | ▼ −7.09% | ▼ −6.65% | $0.2582 (−83.12%) |
|
May 20, 2026
16d ago
|
S-1
| — | awaiting T+1 | — | — |
|
May 6, 2026
4w ago
|
424B4
| $0.2320 $0.2210 | ▲ +4.74% | ▲ +4.41% | $0.2582 (−11.29%) |
|
May 5, 2026
4w ago
|
8-K
| $0.2100 $0.2320 | ▼ −10.48% | ▼ −9.09% | $0.2582 (−22.95%) |
|
Apr 22, 2026
6w ago
|
8-K
| $0.9070 $0.8430 | ▼ −7.06% | ▼ −6.66% | $0.2582 (−71.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access